Table 2.
Comparison of clinical features, treatment details, and outcomes between patients with autoimmune pancreatitis and chronic pancreatitis
| AIP (n = 8) | CP (n = 92) | Pvalue | |
|---|---|---|---|
| Clinical features | Median (range) | ||
| Age (years) | 69.0 (59–73) | 56.5 (20–85) | 0.018* |
| Gender (male/female) | 7/1 | 77/15 | 1.000 |
| Therapeutic purpose for ESWL | |||
| Chronic pain (+/−) | 0/8 | 42/50 | 0.019* |
| Pancreatic attack (+/−) | 1/7 | 32/60 | 0.265 |
| Preservation of pancreatic function (+/−) | 7/1 | 18/74 | <0.001* |
| Treatment details | |||
| Location of treated pancreatic stones | |||
| Pancreatic head | 6/2 | 83/9 | 0.213 |
| Pancreatic body | 3/5 | 15/77 | 0.153 |
| Pancreatic tail | 0/8 | 1/91 | 1.000 |
| Pancreatic duct stenosis proximal to stones (+/−) | 4/4 | 22/70 | 0.107 |
| Endoscopic treatment | 6/2 | 66/26 | 1.000 |
| Endoscopic pancreatic sphincterotomy (+/−) | 3/5 | 39/53 | 1.000 |
| Endoscopic pancreatolithotripsy (+/−) | 3/5 | 45/47 | 0.716 |
| Endoscopic pancreatic stenting (+/−) | 3/5 | 32/60 | 1.000 |
| Outcomes | |||
| Extraction of pancreatic stones in MPD (+/−) | 5/3 | 71/21 | 0.394 |
| Shift to surgical treatment (+/−) | 1/7 | 3/89 | 0.284 |
| Complications associated with ESWL (+/−) | 0/8 | 8/84 | 1.000 |
| Relapse of pancreatic stones in MPD (+/−) | 1/7 | 22/70 | 0.678 |
AIP: autoimmune pancreatitis; CP; chronic pancreatitis; ESWL: extracorporeal shock wave lithotripsy; MPD: main pancreatic duct.
*P < 0.05.